Disease management for progressive disease has recently become the focus of increased attention by MS researchers and clinicians:The interferons???interferon beta 1a (Avonex?? and Rebif??) and interferon beta 1b (Betaseron??)-are approved for people with relapsing forms of MS, which includes those with secondary-progressive disease who have clinical relapses, as well as those with relapsing-progre